Relay Therapeutics, Inc.
RLAY
$7.77
$0.283.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -23.26% | 100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -23.26% | 100.00% | -- |
| Cost of Revenue | -11.39% | -33.18% | -10.43% | -12.78% | -5.98% |
| Gross Profit | 11.39% | 33.91% | 8.66% | 12.78% | -36.11% |
| SG&A Expenses | -36.70% | -31.71% | -5.35% | 0.76% | 6.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.58% | -32.91% | -9.45% | -9.85% | -3.61% |
| Operating Income | 16.58% | 33.52% | 7.95% | 9.85% | -28.88% |
| Income Before Tax | 15.84% | 23.68% | 5.31% | 8.97% | -34.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.84% | 23.68% | 5.31% | 8.97% | -34.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.84% | 23.68% | 5.31% | 8.97% | -34.03% |
| EBIT | 16.58% | 33.52% | 7.95% | 9.85% | -28.88% |
| EBITDA | 16.17% | 33.60% | 7.86% | 9.95% | -29.41% |
| EPS Basic | 31.55% | 40.82% | 26.78% | 32.14% | -16.83% |
| Normalized Basic EPS | 31.55% | 49.04% | 28.40% | 33.78% | -14.72% |
| EPS Diluted | 31.55% | 40.82% | 26.78% | 32.14% | -16.83% |
| Normalized Diluted EPS | 31.55% | 49.04% | 28.40% | 33.78% | -14.72% |
| Average Basic Shares Outstanding | 22.93% | 28.94% | 29.34% | 34.14% | 14.72% |
| Average Diluted Shares Outstanding | 22.93% | 28.94% | 29.34% | 34.14% | 14.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |